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Aim: While it is known that severe COPD has substantial economic consequences, evidence on
resource use and costs in mild disease is scarce. The objective of this study was to investigate
excess costs of early stages of COPD.
Methods: Using data from two population-based studies in Southern Germany, current GOLD
criteria were applied to pre-bronchodilator spirometry for COPD diagnosis and staging in
2255 participants aged 41 to 89. Utilization of physician visits, hospital stays and medication
was compared between participants with COPD stage I, stage IIþ (II or higher) and controls.
Costs per year were calculated by applying national unit costs. In controlling for confounders,
two-part generalized regression analyses were used to account for the skewed distribution of
costs and the high proportion of subjects without costs.
Results: Utilization in all categories was significantly higher in COPD patients than in controls.
After adjusting for confounders, these differences remained present in physician visits and
medication, but not in hospital days. Adjusted annual costs did not differ between stage I
(V 1830) and controls (V 1822), but increased by about 54% to V 2812 in stage IIþ.9 3187 4166; fax: þ49 89 3187 3375.
holtz-muenchen.de (P. Menn).
.-E. Wichmann (speaker), R. Holle, J. John, T. Illig, C. Meisinger, A. Peters, and their coworkers, who
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Direct medical excess costs of COPD 541Conclusion: The finding that utilization and costs are considerably higher in moderate but not
in mild COPD highlights the economic importance of prevention and of interventions aiming at
early diagnosis and delayed disease progression.
ª 2011 Elsevier Ltd. All rights reserved.Background
Chronic obstructive pulmonary disease (COPD) is a common
chronic condition that has many systemic effects apart
from pulmonary impairment. COPD patients are at
increased risk e.g. for myocardial infarction, diabetes and
depression. The recently published BOLD study found
a prevalence of COPD of 13.2% in the population aged 40
years and older in Germany according to the GOLD classi-
fication; most patients had mild disease, with a prevalence
of 7.4%.1
Cost estimates of a disease are needed to assess its
overall burden as well as to inform policy decisions.
Although COPD has substantial economic consequences,
little is known about the effect on medical costs in early
disease stages as many studies excluded patients with mild
disease.2,3 A Swedish study that did include patients across
all disease stages found that, although patients with mild
COPD often had no prior diagnosis and generally incur low
costs, these patients accounted for a substantial part of the
total societal costs of COPD, due to the high prevalence of
mild COPD in the general population.4
As it is known that treatment patterns as well as unit
costs of healthcare goods and services differ between
countries, transferability of cost estimates across settings is
rather low, and cost differences between countries have
been found to be large. The Confronting COPD survey,
which was conducted in 2000/01 in seven countries in
Europe and North America (Canada, France, Italy, Nether-
lands, Spain, UK and USA), found mean annual direct costs
of COPD in previously diagnosed patients ranging from US$
522 (France) to US$ 4119 (US).5 Therefore, country-specific
data are needed that are derived within the respective
healthcare setting.
To date, one cost of illness study is available that esti-
mated costs of COPD in Germany. Nowak et al. included
patients with FEV1 < 70% and found annual COPD-related
costs of V 3027 per patient.6 However, patients with
milder disease were not included, and a previous diagnosis
of COPD was required for inclusion. Moreover, this previous
study followed an attributable cost approach to estimate
costs of COPD, where only service use due to COPD is
considered. In contrast, excess costs are calculated as the
difference in the overall costs between COPD patients and
subjects without COPD considering all costs regardless of
the underlying diagnosis.7 Conceivably, such an excess cost
approach gives a more adequate estimate of the impact of
a disease on overall healthcare costs. In Germany, the
majority of direct medical costs are compulsorily financed
by society, which is a strong motivation for the government
to intervene in the increasing prevalence of COPD and
reduce the costs related to it. However, information on
resource use and costs associated with early stages of COPDin Germany is largely lacking, and until now, no data on
excess costs particularly of mild COPD are available.
The aim of this study was to compare healthcare utili-
zation between patients with mild and moderate COPD and
subjects without lung obstruction from two population-
based cohorts and to calculate direct medical excess costs
of COPD.
Methods
Study population
Data from two population-based KORA studies (Cooperative
Health Research in the Region of Augsburg) were analyzed:
KORA F4, a follow-up of the KORA Survey 2000,8 was con-
ducted from 2006 to 2008, and lung function measurements
were performed in a subcohort of 1324 subjects aged 41e61
years. KORA-Age was conducted in 2008/09 as a follow-up
of all participants aged 65 and above of the MONICA/
KORA surveys S1 to S4, and a medical examination was
conducted in a random sub-sample of the cohort aged 65 to
89 (nZ 1079). Lung function was measured in 934 of these
participants (E-Figure 1).9 So the entire sample for this
study included 2259 individuals. Written informed consent
was obtained from all participants, and the studies were
approved by the Ethics Committee of the Bavarian Medical
Association. Details about design, sampling method and
data collection for the two studies are given in the online
supplement and have also been published previously.10,11
Briefly, spirometry was performed using a pneumotacho-
graph-type spirometer (Masterscreen PC, CareFusion, Ger-
many). The spirometer was calibrated at least once a day
before measurements, and additionally, an internal control
was used to ensure constant instrumental conditions. The
participants performed at least three forced expiratory
lung function manoeuvers in order to obtain a minimum of
two acceptable and reproducible values. Spirometric
measurements were in line with the ATS guidelines with the
following exception: the values of FVC and FEV1 were
determined from the best manoeuver, which was defined as
the trial with the highest sum of FVC and FEV1. Predicted
values were calculated from reference equations provided
by the European Community for Steel and Coal.12
COPD
The definition of COPD and staging of severity were based
on pre-bronchodilator spirometry. Classification of disease
severity was defined according to modified GOLD classifi-
cation13. Participants with an FEV1/FVC ratio (ratio of
forced expiratory volume in 1 s and forced vital
capacity)  0.7 were defined as non-COPD group, those
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pred: FEV1% pred  80 (Stage I), 80 > FEV1% pred  50
(Stage II), 50 > FEV1% pred  30 (Stage III) and FEV1%
pred < 30 (Stage IV). For analysis, stages II, III and IV were
combined into stage IIþ.
Covariables
In addition to age and sex, socio-economic variables and
self-reported data on comorbidity were obtained through
computer-assisted interviews that were performed face-to-
face in KORA F4 and by phone in KORA-Age. Educational
level was categorized into basic (11 years) and high (>11
years), and smoking status was classified as never-smoker,
former smoker and current smoker. For participants with
missing information on education (n Z 4), the most
frequent category (basic education) was assumed. The
presence of 8 frequent comorbid conditions was also stated
by the participants. These included arthritis, cancer, dia-
betes, gastrointestinal disease, coronary heart disease,
renal disease, liver problems, and stroke. The choice of
these conditions was based on a self-reported version of the
Charlson comorbidity index14; we did not consider HIV/AIDS
as no subjects affected with the disease were included in
our population sample.
Resource use and costs
Within computer-assisted interviews, participants were
asked about their utilization of outpatient and inpatient
services and drugs. The interviews were performed face-to-
face in KORA F4 and by phone in KORA-Age. Outpatient
services were assessed by asking the questions ‘Have you
seen a physician (general practitioner or specialist) in the
past 3 months?’, and if ‘yes’, ‘How often did you see
a particular physician in the past 3 months?’ with regard to
14 different types of physicians and specialists, excluding
dentists. For inpatient services, the number of hospital
days was assessed by asking ‘Have you been hospitalized in
the past 12 months?’, and if ‘yes’, ‘How many days have
you been hospitalized in the past 12 months?’. Drug
consumption covered the medications taken in the past 7
days including both prescription drugs and over-the-counter
medicines.
To obtain annual costs, physician visits were extrapo-
lated from 3 to 12 months by multiplying the self-reported
number of physician visits by 4, while for drug consumption,
information on the frequency and amount of drug intake
was used to estimate the number of medication packages
needed per year. Where this information was not available,
defined daily doses were applied to assess the annual
number of packages.
Costs were assessed from a broader health system
perspective, which in addition to the costs borne by the
third party payers includes the co-payments by the patients
as well as the tax-financed subsidies for the fixed capital
investments in the hospital sector. To calculate direct
medical excess costs, the frequency of service use was
multiplied with unit costs. Unit costs per hospital day and
per physician visit were based on the recommendation of
the German Working Group on Methods in Health EconomicEvaluation,15 where specific standard cost rates for each
unit have been proposed based on administrative charges or
official statistics. Costs were inflated to 2008 price levels
using the percent change in physician payment per case for
physician rates, and data from the federal statistical office
for hospital rates, yielding unit costs of V 19.10 per visit at
the general physician, costs from V 18.30 to V 56.61 per
specialist visit, and V 509 per hospital day. Drug costs were
calculated from pharmacy retail prices of the year 200816
by subtracting discounts of manufacturers and pharmacies
according to the Social Security Code. Details on how costs
were estimated can be found in the online supplement (E-
Table 1) together with additional background information
on the German healthcare system. Total direct medical
costs were then calculated as the sum of outpatient,
inpatient, and drug costs.
Additionally, medication costs attributable to COPD
were assessed as the sum of the costs for the following
drugs: long- and short-acting beta-agonists, inhaled corti-
costeroids, anticholinergics, and xanthines.Statistical analysis
Baseline characteristics of subjects without COPD, with
COPD stage I and COPD stage IIþ were compared using
analysis of variance (ANOVA) for continuous and Chi-
squared tests for categorical variables. Unadjusted values
of utilization and costs were compared between the three
groups using KruskaleWallis tests; if differences between
the three groups were observed, pairwise comparisons
were conducted between stage I and controls, stage IIþ and
controls, and stage I and stage IIþ. In adjusting for possible
confounders, generalized linear regression analyses were
conducted to account for the typically highly skewed
distribution of both utilization and costs. For utilization,
a negative binomial distribution was assumed, as data
showed signs of overdispersion.17 Two-part regression
models were used for costs to take into account the large
number of zero values, where the first part used a logistic
regression to predict the probability of positive costs, while
a gamma model with log-link was used in the second stage
to analyze positive expenditures.18 The exponents of the
regression coefficients from the gamma model are pre-
sented, which can be interpreted as factors, i.e. a covari-
ate with a coefficient of 1.3 is associated with an increase
in costs by 30%. The basic model included age, sex and
educational level as covariates, as an association between
COPD and socio-economic status is known e.g. in terms of
rates of severe exacerbations.19 This basic model provides
actual excess costs. The choice of the Gamma distribution
was confirmed by the modified Park test, and several
goodness-of-fit tests indicated the acceptability of the log-
link function (Pearson correlation test: p Z 0.86, Pre-
gibon’s link test: p Z 0.78, modified HosmereLemeshow
test: p Z 0.69).20
Most of the previous studies on excess costs of COPD
additionally adjust for smoking21 and some form of
comorbidity.22,23 In order to provide results that are
comparable to those from the literature, we calculated an
extended model as a sensitivity analysis, where we
adjusted for smoking status as well as for comorbidity by
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conditions. Also, analyses were rerun by omitting patients
with severe or very severe COPD (stages III and IV), limiting
stage II þ to patients with stage II only.
To examine group differences, we used recycled
predictions (also called predictive margins), which are
commonly used to estimate absolute cost differences
between groups in generalized regression analysis.24,25
Also, they allow assessing the overall effect of COPD on
costs across both steps of the two-part model by combining
the effect on the probability of having positive costs and on
the amount of costs given costs are greater than zero.
Based on the regression estimates, three predictions are
derived: First, assuming all subjects have no COPD; second
assuming that all have COPD stage I; and third assuming
that all have COPD stage IIþ. The mean differences
between these predictions are excess costs of COPD
adjusted for covariates. 95% confidence intervals (CI) for
the adjusted cost differences were estimated from 2000
bootstrap replications using the percentile method.
Analyses were performed using the software package
SAS, version 9.2. P-values of 0.05 or less were considered
statistically significant.
Results
Patients
Valid spirometry measurements were available for 2255 of
the 2259 subjects. In all, 375 or 16.6% were categorized as
having COPD based on pre-bronchodilator lung function. Of
these, 267 (71%) were in stage I, 108 in stage IIþ (99 in stage
II, 7 in stage III, and 2 in stage VI). Prevalence was 9% inTable 1 Patient characteristics according to COPD status.
no COPD
(n Z 1880)
C
(n
Age, years 60.1 (12.7) 6
Male (%) 47% 5
Educational level (%)
Basic (11 years) 73% 7
Higher (>11 years) 27% 2
Smoking (%)
Current smoker 14% 1
Ex-smoker 38% 4
Never-smoker 48% 3
Comorbid conditions (%)
Arthritis 9.9% 1
Cancer 8.0% 1
Diabetes 8.7% 8
Gastrointestinal disease 4.2% 3
Coronary heart disease 3.9% 7
Renal disease 5.3% 3
Liver problems 1.4% 3
Stroke 3.2% 3
Data are mean (standard deviation) and percent.
a p-value based on ANOVA.
b p-value based on Chi2-test.
c p-value based on Fisher’s exact test.those aged 40e49, and increased to 35% in those aged 80
and above. According to self-reported information, about
75% of the COPD patients had no prior diagnosis of COPD.
Patient characteristics by COPD status are shown in Table 1.
COPD patients were older than non-COPD participants and
were more likely men. Also, patients with COPD showed
higher comorbidity, with significant differences in coronary
heart disease, liver problems and history of a stroke. The
educational level did not differ between groups.Healthcare utilization
Table 2 shows the percentage of users and the frequency of
resource use according to COPD status. Differences were
significant for all three healthcare services, with higher
utilization in COPD patients than in controls. The total
number of outpatient visits did not differ between stage I
and stage IIþ (p Z 0.69), but stage I patients reported
slightly more visits at general practitioners, while in stage
II þ more visits at specialists were reported. Compared to
non-COPD participants, an increase in hospital days was
observed in stage IIþ (pZ 0.01), but not in stage I (pZ 0.09).
Both the prevalence of drug consumption and the number of
medications taken was higher in stage I and in stage
IIþ compared to the group without COPD. The proportion of
stage I patients who reported taking COPD-related medica-
tion (beta-agonists, inhaled corticosteroids, anticholiner-
gics, xanthines) was 10%,which increased to 26% in stage IIþ.
After adjusting for sex, age, and educational level, COPD
status was still associated with more outpatient visits and
drug consumption, but not with increased hospital days
(Table 3). Additional adjustment for smoking status and
comorbidity only slightly affected these findings.OPD stage I
Z 267)
COPD stage IIþ
(n Z 108)
p-value
7.8 (13.5) 67.6 (13.4) <0.001a
5% 60% 0.002b
2% 77% 0.574b
8% 23%
8% 29% <0.001b
5% 39%
7% 32%
1.2% 13.9% 0.332c
0.5% 10.2% 0.281c
.6% 15.7% 0.057c
.7% 5.6% 0.682c
.1% 13.9% <0.001c
.7% 4.6% 0.589c
.0% 3.7% 0.031c
.4% 8.3% 0.030c
Table 2 Unadjusted healthcare utilization and costs (V).
no COPD
(n Z 1880)
COPD stage I
(n Z 267)
COPD stage IIþ
(n Z 108)
p-value
Utilization
Outpatient services (3 months)
% Users 70% 81%d 83%d <0.0001a
Total number of visits 3.01 (4.11) 4.06 (4.72)d 4.14 (5.65)d <0.0001b
General practitioner 1.28 (2.14) 1.87 (2.76)d 1.68 (1.65)d
Specialist 1.72 (3.02) 2.19 (3.42)d 2.46 (5.26)d
Inpatient services (12 months)
% Users 14% 18% 22%d 0.0273a
Number of hospital days 1.76 (11.48) 1.92 (5.57) 3.62 (12.34)d 0.0161b
Drug consumption (7 days)
% Users 73% 82%d 86%d 0.0002a
Beta-agonists 1.4% 7.9%d 22.2%d,e <0.0001c
Inhaled corticosteroids 1.2% 2.2% 3.7%d 0.0402c
Anticholinergics 0.3% 0.4% 6.5%d,e <0.0001c
Xanthines 0.1% 1.1%d 2.8%d <0.0001c
Number of drugs 2.53 (2.74) 3.40 (2.92)d 3.93 (3.10)d <0.0001b
Prescription drugs 1.89 (2.24) 2.65 (2.48)d 3.27 (2.76)d,e <0.0001b
Costs (12 months)
Total costs [mean (IQR)] 1782 [154e1663] 2034 [313e2136]d 3119 [437e3056]d <0.0001b
Outpatient costs 329 [0e408] 443 [76e611]d 466 [76e623]d <0.0001b
Inpatient costs 897 [0e0] 978 [0e0] 1843 [0e0]d 0.0161b
Drug costs 556 [0e692] 613 [80e936]d 810 [170e1201]d,e <0.0001b
Data are mean (standard deviation), mean [interquartile range] and percent.
a p-value based on Chi2-test.
b p-value based on KruskaleWallis test.
c p-value based on Fisher’s exact test.
d differs significantly from those without COPD.
e differs significantly from stage I; IQR: interquartile range.
Table 3 Regression coefficients of the negative binomial models on utilization with and without adjusting for comorbidity by
healthcare service.
Covariate Number of outpatient visits
(3 months)
Number of hospital days
(12 months)
Number of drugs
(7 days)
Basic modela Extended modelb Basic modela Extended modelb Basic modela Extended modelb
Intercept e0.374* e0.183 0.028 e0.646 e1.730*** e1.801***
Age 0.021*** 0.013*** 0.014 0.014 0.037*** 0.030***
Gender: Female 0.138** 0.194*** e0.142 e0.087 0.225*** 0.339***
High education e0.099 e0.079 e0.162 0.189 e0.064 e0.010
COPD stage I 0.163* 0.222** e0.106 0.032 0.052 0.083
COPD stage IIþ 0.195 0.154 0.508 0.248 0.249** 0.176*
Former smoker 0.121 0.105 0.033
Current smoker 0.068 0.144 0.176***
Arthritis 0.355*** e0.096 0.272***
Cancer 0.365*** 0.715 0.164*
Diabetes 0.309*** 0.318 0.611***
Gastrointestinal disease 0.294* 0.361 e0.012
Coronary heart disease 0.289* 0.714 0.481***
Renal disease 0.094 1.759*** 0.429***
Liver problems 0.028 1.909* 0.391**
Stroke 0.316* 0.871 0.262**
*p < 0.05; **p < 0.01; ***p < 0.001.
a Adjusted for age, sex and education only.
b Adjusted for age, sex, education, smoking status and comorbidity.
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Figure 1 Impact of individual cost components on adjusted
total direct medical costs by COPD status (mean costs are
adjusted for age, sex and education; 95% confidence intervals
for total direct medical costs [based on 2000 bootstrap repli-
cations using the percentile method]).
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Unadjusted mean total costs are shown in Table 2. 14% of
all participants incurred no costs, and mean total direct
medical costs ranged from V 1782 in participants without
COPD to V 3119 in stage IIþ, so patients with COPD stage I
and II þ incurred 14% and 75% higher costs than controls,
respectively. Medication costs attributable to COPD were V
16 in the control group, and increased to V 68 and V 178 in
stage I and stage IIþ, respectively (p-value <0.0001).
Results of the basic and the extended regression model
on costs are given in Table 4. Adjusting for covariates, both
showed no effect of COPD on the probability of positive
costs, but a significant effect of stage II þ on the amount of
costs for those with positive costs. In the basic model, stage
IIþ was associated with an increase in costs by 51% in the
second model step, which reduced to 29% after additional
adjustment for smoking status and comorbidity. Older
participants and females had a significantly higher proba-
bility of incurring costs, but the amount of costs was not
associated with sex. In the basic model, costs increased
with increasing age, however, this effect was no longer
significant after adjusting for comorbidity. Adjusted mean
costs in the basic model, which particularly account for the
age difference of about 8 years between COPD patients and
controls, were V 1822 in the non-COPD group, V 1830 in
stage I and V 2812 in stage IIþ, yielding excess costs of V
990 (95% CI V -66 e 1751) for stage IIþ. The contribution of
the individual cost components on adjusted total costs by
COPD group is shown in Fig. 1. Drugs and hospital stays
accounted for 31% and 50%, respectively, of adjusted total
costs in participants without COPD, for 30% and 49% in stageTable 4 Regression coefficients of the two-part model on total
Covariate
First part:
probability of costs > 0
(logistic regression
modela)
Basic modelc Extended mo
Age 1.080*** 1.062***
Gender: Female 2.428*** 2.527***
High education 0.825 0.863
COPD stage I 0.904 0.902
COPD stage IIþ 1.234 1.163
Former smoker 0.920
Current smoker 1.109
Arthritis 2.114*
Cancer 2.789*
Diabetes 5.964**
Gastrointestinal disease 2.783
Coronary heart disease 7.340
Renal disease 0.966
Liver problems 3.997
Stroke 5.822
*p < 0.05; **p < 0.01; ***p < 0.001.
a Given as Odds Ratios.
b Given as exp(regression estimate).
c Adjusted for age, sex and education only.
d Adjusted for age, sex, education, smoking status and comorbidityI, and for 27% and 58% in stage IIþ. After additionally
adjusting for smoking status and comorbidity, the excess
costs were V 186 (95% CI V -299 e 544) in stage I and V 568
(95% CI V -240 e 1216) in stage IIþ. The impact of the
comorbid diseases varied from mean excess costs of V 485
in arthritis to V 3524 and V 4488 in renal and liver disease,
respectively.
Rerunning the analyses without patients with severe and
very severe COPD did not affect the results, nor did the
inclusion of season as an additional possible confounder
(data not shown).costs with and without adjusting for comorbidity.
Second part:
amount of costs for
those with positive costs
(gamma regression model with Log-linkb)
deld Basic modelc Extended modeld
1.006** 1.003
0.915 1.001
0.931 1.099
1.017 1.113
1.508** 1.291*
0.982
0.967
1.190*
1.726***
1.378***
1.259
1.562***
3.068***
3.185***
1.652***
.
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The objective of this study was to compare healthcare utili-
zation between patients with mild and moderate COPD and
subjects without lung obstruction, and to calculate direct
medical excess costs of COPD based on two population-based
cohorts. We found increased utilization with regard to
outpatient visits and drug consumption in COPD. After
adjusting for differences in age, gender and education, costs
did not differ between patients in stage I and controls, but
were increased by V 990 in stage II þ compared to controls.
Previous studies have shown that absolute treatment
costs increase dramatically with disease stage, and are
substantial even in mild COPD,4,26 while most studies that
focused on excess costs did not include patients with mild
disease.21 In our study, we also observed higher costs in
more advanced disease, but costs in stage I differed only
marginally from those of subjects with normal lung func-
tion. Hospital costs accounted for 49% of all direct costs in
stage I and 58% in stage IIþ, respectively. This is in line with
results of previous studies, where costs of hospital stays
represented 40e57% of all direct costs, and could be as
much as 63% in severely ill patients.27
After including smoking status and comorbidity in the
model, excess costs were reduced by 43%, indicating that
a considerable part of COPD excess costs are attributable to
increased prevalence of other diseases in this patient
group. This is in line with findings from the US, where
35e38%22 and 46%23 of total excess costs of COPD were
explained by comorbid conditions. We also found that after
controlling for comorbidity, age was no longer a predictor
for the amount of costs. This also agrees with results of
previous studies showing that not increasing age is not per
se a risk factor for high costs, but rather a proxy for
increasing comorbidity in older patients, and that comor-
bidity causes the rise in healthcare costs.28
In the only cost-of-illness study on COPD in Germany so
far,6 absolute treatment costs in patients with an FEV1 of
50e70% pred were V 2667 (inflated to 2008 using the
consumer price index), with V 1522 attributable to hospital
stays, physician visits and medication. Although only COPD-
related costs were considered, whereas we followed an
excess cost approach where all costs regardless of the
underlying cause are included, costs for stage IIþ were
somewhat lower in our study. However, Nowak et al.6
referred to patients recruited via physicians, whereas
about 75% of the patients in our study had no prior diag-
nosis, which might explain some of the differences. As
underdiagnosis of COPD is known to be high especially in
early stages, with as few as 5% of patients with mild COPD
reporting a previous diagnosis,29 this probably has led to
the inclusion of a higher proportion of severe cases than in
an unselected sample of the general population, and
consequently in an overestimation of costs.
Studies in other countries such as the US or Denmark also
found higher excess costs of COPD (of about V 4500,30 $US
5000 to $US 6500,22,31 or even $US 20,50023), but these
studies were based on claims data. As disease severity is
not available in those data, stage-specific costs cannot be
derived. These studies also included previously diagnosed
patients only, and the patient sample can be expected to
have contained a higher proportion of severe or very severecases than our cohort. Moreover, the definition of COPD
relied on resource use within in- or outpatient care with
a coded diagnosis of COPD, which may again lead to an
overestimation of excess costs, as less severe cases are
often undiagnosed. Studies in which the diagnosis of COPD
is directly based on lung function, as common in GOLD
definitions, can avoid this bias.
Considering disease severity, a Swedish study found
average annual costs per patient with mild disease of V 194
(2001),4 while in an Italian study costs per patient per year
were V 1047 for mild and V 2319 for moderate COPD.26 A
population-based study in Norway found median excess
costs of V 672 (V 400 after adjusting for the number of
comorbid conditions) in stage II, but did not include patients
withmild COPD.21 Yet thesemedian costs can not be directly
compared to our mean excess costs. Focusing on median
costs is one way to account for the skewed distribution of
costs. However, as mean costs are the main interest for
policy makers,18 we chose the alternative approach of
generalized linear models to deal with this problem.
One strength of our study is the population-based
approach, which allowed the estimation of excess costs by
comparing costs of patients with those of participants with
normal lung function. As COPD often shows substantial
systemic involvement beyond pulmonary impairment, the
alternative approach of considering only COPD-related costs
is problematic and may lead to an underestimation of costs
of the disease. Also, as subjects were a random selection
from the general population, our results may be better
transferable to the overall German situation than those
based on samples recruited by general physicians or
specialists. Additionally, our diagnosis of COPD was based on
spirometry, which avoids the problem of the high proportion
of undiagnosed patients particularly in early disease. These
patients were also not captured in studies based on claims
data, which could result in both an overestimation of costs
per patient and in an underestimation of the overall burden
of the disease. Another advantage of our study is that
patients with mild disease were also included. So far, data
on the economic impact of early stages of COPD have been
scarce. It has been argued that, although costs of mild COPD
are lower than those ofmore advanced disease, its economic
impact might still be considerable due to the high number of
patients concerned.32 Yet our results indicated that excess
costs of mild disease are relatively small.
We also present results after adjusting for specific
comorbidities. While most other studies only adjusted for the
presence of comorbidity32 or the number of comorbid condi-
tions,21 the inclusion of individual diseases allowed the
identification of comorbidities with a high impact on health-
care costs. Apart from the presence of gastrointestinal
disease all conditions considered had a significant effect on
costs, but effect sizes differed considerably, with renal and
liver disease showing the highest impact. These differences
are ignored if only the number of concomitant diagnoses is
included without adjusting for the severity of the disease.
One limitation of our study is the use of unit costs for in-
and outpatient visits. This does not allow accounting for
differences in the volume of resources consumed per visit. If
COPD patients require more or less costly treatment per
hospital day than controls, this approach leads to a biased
estimation of COPD excess costs. Also, our study only
Direct medical excess costs of COPD 547considered costs for in- and outpatient services as well as for
drug consumption, which in 2008 added up to about 55% of
total healthcare expenditure across all diseases. Due to data
limitations, we could not include other important compo-
nents of medical costs such as long-term care, rehabilita-
tion, and medical aids. Moreover, direct non-medical costs
such as transportation as well as indirect costs due to
productivity loss are not included in our analysis. As an
inclusion of these components would most likely lead to
higher excess costs of COPD, our results can be seen as
conservative estimates of the true burden of COPD.
An alternative to using the fixed ratio of FEV1/FVC < 0.7
for the definition of COPD is the lower limit of normal (LLN).
Differences between these two definitions are usually small
in lower age groups, but can be more relevant in older age
groups, where fewer subjects are classified as having COPD
based on LLN criteria than using the fixed ratio. It can
therefore be assumed that excess costs would be higher by
applying the LLN criteria where more subjects with mild
obstruction are not classified as COPD patients.
Also, diagnosis of COPD was based on pre-bronchodilator
spirometry, so misclassification of asthmatic subjects as
COPD patients and therefore over-diagnosis particularly of
mild disease cannot be excluded.33 Post-bronchodilator
spirometry was available from 938 out of 1324 subjects
from F4 (71% of the F4 cohort). Using post-bronchodilator
measurements to define COPD only marginally affected
excess costs of the F4 subgroup. However, standard errors
increased as the number of COPD cases was substantially
reduced (from 136 to 61), because participantswho reported
a history of myocardial infarction within the last month,
angina pectoris, hypertrophic obstructive cardiomyopathy,
and hyperthyroidism had been excluded from post-
bronchodilator spirometry. The same was true for subjects
who reported taking beta blockers, digitalis or diuretics.
In this retrospective study, assessment of utilization was
based on self-report, which is prone to recall bias. It has
been shown that a time frame of one year is appropriate for
services that are rarely used, such as hospitalization,
whereas shorter time frames are recommended for more
frequently used components of care, such as physician
visits.34 We tried to minimize potential recall bias by
applying different time horizons for the individual care
components. Although the amount of this possible bias is
unknown, it is likely to only affect absolute cost estimates
moderately but not differences between groups. Also,
information on comorbid conditions was based on self-
reports and therefore less valid than e.g. information
from medical records. However, we only included relatively
well-defined diseases, where validity has been shown to be
good.35 In contrast, COPD itself, where validity has been
found to be fairly low, was based on objective lung function
measurement.36 However, in few cases (n Z 49), partici-
pants with normal lung function reported taking medication
treating COPD, indicating a possible misclassification of
these subjects. However, excluding these individuals from
the analyses did not change the results. Another limitation
associated with the retrospective nature of the study is
a possible selection bias in our study sample. With non-
participants likely being more impaired than participants,
our sample might not be representative of the German
population, which limits the generalizability of our findingsand needs to be kept in mind when interpreting results.
However, this bias can be expected to be more serious in
more severe disease stages. Furthermore, the low number
of patients with COPD stage III and IV does not allow
separate analyses for these stages. As population-based
studies are not suitable to analyze these advanced and
relatively rare disease states, special patient cohorts are
needed that provide sufficient cases of severe COPD.
Finally, as our definition of COPD was based on lung
function only, and other clinical factors such as exposure to
risk factors or the presence of symptoms were not consid-
ered, our patient group differs from a clinical sample.
In conclusion, as excess costs of mild disease per se
appear to be small, preventing COPD patients from
progression to more severe stages is important not only from
a clinical but also from an economic perspective. Interven-
tions e.g. focusing on smoking cessation, which has been
shown to be one of the most efficient interventions to slow
disease progression, can help to reduce treatment costs.
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